Goldman Sachs Upgrades Genmab A/S (GMAB) to Buy

Goldman Sachs analyst Rajan Sharma upgraded Genmab A/S (NASDAQ: GMAB) from Neutral to Buy with a price target of $30.50 (from $24.50).

For an analyst ratings summary and ratings history on Genmab A/S click here. For more ratings news on Genmab A/S click here.

Shares of Genmab A/S closed at $27.06 yesterday.

You May Also Be Interested In

• Deutsche Bank Downgrades L'Oreal SA (OR:FP) (LRLCY) to Sell
• Synthomer Plc (SYNT:LN) (SYHMY) PT Raised to GBP0.92 at Deutsche Bank
• Wolfe Research Upgrades Target (TGT) to Outperform